Biopharma Advances Fueling Enhanced Disease Management

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; seq

Table of Contents

Biopharma Advances Fueling Enhanced Disease ManagementRecent Biopharma AdvancesNovel Gene Therapy for CystinosisNovel Tissue-Engineered Blood Vessel GraftBig Pharma Collaboration for RNAi TherapyAvidBiotics Splits to Form Two New CompaniesClinical Trial Analysis and Industry InteractionsSummary of Active Clinical Trials Evaluating RNAi TherapySummary of Key Contacts

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.